| Molecular formula | C30H54N6O5 |
| Molecular weight | 578.8 g/mol |
| Registered trials | 0 |
| PubChem CID | 10231864 |
| Brand names | BUDDATE REGES INTENSIVE TREATMENT |
Key takeaways
- Palmitoyl tripeptide-1 is a synthetic peptide with the molecular formula C30H54N6O5 and a molecular weight of about 578.8 g/mol.
- It is listed as the active ingredient in a topical cosmetic product called BUDDATE REGES INTENSIVE TREATMENT.
- The labeling describes topical application to the skin rather than treatment of a specific medical condition.
- No boxed warning appears on the product labeling.
- No clinical trials are currently registered for this compound, and no adverse event reports were found in the data reviewed.
What palmitoyl tripeptide-1 is
Palmitoyl tripeptide-1 is a small synthetic peptide built from a short amino acid chain attached to a fatty (palmitoyl) group. Its structure corresponds to molecular formula C30H54N6O5 with a molecular weight near 578.8 g/mol, and it is catalogued under PubChem CID 10231864. No mechanism of action or pharmacologic class has been specified in the label data reviewed.
What palmitoyl tripeptide-1 is approved for
The reviewed labeling covers a topical cosmetic product, BUDDATE REGES INTENSIVE TREATMENT, that contains palmitoyl tripeptide-1. The label instructs applying the cream to the skin multiple times a day and massaging it in gently. This is a cosmetic-style skin care use rather than treatment of a diagnosed disease, and the labeling does not describe any boxed warning.
FAQ
Palmitoyl tripeptide-1 is a synthetic peptide with a fatty acid group attached, chemically defined as C30H54N6O5 with a molecular weight of about 578.8 g/mol. It is catalogued in PubChem under CID 10231864. It appears as an ingredient in a topical cosmetic skin care product.
In the reviewed labeling, palmitoyl tripeptide-1 is an ingredient in a topical cream meant to be applied to the skin and massaged in. The label frames this as general skin care rather than treatment of a specific medical condition.
No, the labeling reviewed for this product does not carry a boxed warning.
No adverse event reports were found for this compound in the FDA data reviewed. This means no side effect pattern can currently be summarized from that source, not that side effects are absent.
No registered clinical trials for palmitoyl tripeptide-1 were found in the data reviewed. As a result, no trial phase, design, or outcome information is available to summarize.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: DailyMed label PubChem
Updated 2026-08-04